Tyrphostin AG528 is widely used in biomedical research as a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is commonly applied in studies involving cell signaling pathways, particularly those related to cell proliferation, differentiation, and apoptosis. Due to its ability to block EGFR autophosphorylation, it serves as a valuable tool in cancer research, especially in models of tumor growth and metastasis where EGFR overexpression plays a key role. It has been used in vitro to suppress the growth of various cancer cell lines, including breast, lung, and ovarian cancers, helping to elucidate the role of tyrosine kinase activity in oncogenesis. Additionally, Tyrphostin AG528 is employed to investigate insulin signaling, as it can modulate insulin receptor activity and downstream metabolic effects in cellular models. Its application extends to the study of neurodegenerative diseases and diabetic complications, where aberrant kinase signaling contributes to disease progression. Researchers use it to dissect molecular mechanisms and evaluate potential therapeutic strategies by selectively inhibiting tyrosine kinase activity in experimental systems.